drugset / Trial / NCT04914286

A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors

NCT04914286

Phase 1/2 Completed 148 enrolled Genfleet Therapeutics (Shanghai) Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety/tolerability, pharmacokinetics, and preliminary efficacy of GFH018 in combination with Toripalimab in patients with advanced solid tumors.

Timeline

Start
2021-10-20
Primary completion
2023-12-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject GFH018 Small molecule Oral
Subject Toripalimab Monoclonal antibody 3 mg/kg Intravenous

Indications

No indication recorded.